Corporate Profile

To become a world leader in the development of targeted antiviral therapies for chronic hepatitis B (CHB) and COVID-19 and to leverage our expertise in liver diseases to create optimized therapeutics for NASH.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events

More events are coming soon.

SEC Filings

Filing date Form
3
3